Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway

Context: Heart failure (HF) is one of the most serious diseases worldwide. Astragaloside IV (ASI) is widely used for the treatment of cardiovascular disease in China. Objective: To evaluate the protective effect of ASI on the HF in a Sprague–Dawley rat model of left coronary artery ligation, and inv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yan-Bo Sui, Yu Wang, Li Liu, Feng Liu, Yi-Qing Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2019
Materias:	left coronary artery ligation cd31 vegf rna interference Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/30fc41ab8e72464fab9085b4d9139a56
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:30fc41ab8e72464fab9085b4d9139a56
record_format	dspace
spelling	oai:doaj.org-article:30fc41ab8e72464fab9085b4d9139a562021-11-17T14:21:55ZAstragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway1388-02091744-511610.1080/13880209.2019.1569697https://doaj.org/article/30fc41ab8e72464fab9085b4d9139a562019-01-01T00:00:00Zhttp://dx.doi.org/10.1080/13880209.2019.1569697https://doaj.org/toc/1388-0209https://doaj.org/toc/1744-5116Context: Heart failure (HF) is one of the most serious diseases worldwide. Astragaloside IV (ASI) is widely used for the treatment of cardiovascular disease in China. Objective: To evaluate the protective effect of ASI on the HF in a Sprague–Dawley rat model of left coronary artery ligation, and investigate the angiogenesis-related mechanisms. Materials and methods: Left coronary artery was ligated to induce a rat model of HF, and the rats were treated with vehicle (saline) or different doses of ASI (0.1, 0.3 and 1 mg/kg/day) by oral gavage for 6 weeks. Cardiac function was evaluated by echocardiography. Infarct size was determined by triphenyltetrazolium chloride staining. Cardiac vascular density was analyzed by microangiography. Real-time PCR, Western blot and chromatin immunoprecipitation were performed to investigate the mechanisms. Results: ASI treatment improved the body weight and survival rate of HF rats, as well as the cardiac function of HF rats, with significantly improved ejection fraction (75.27 ± 5.75% vs. 36.26 ± 4.14%) and fractional shortening (45.39 ± 3.66% vs. 17.88 ± 1.32%). ASI reduced the infarct size of the HF rats by 47%. ASI promoted angiogenesis, with increased vascular density (2.08-fold) and induced mRNA expression of CD31 (1.81-fold) and VEGF (2.70-fold) in the ischemic heart. Furthermore, ASI induced the phosphorylation of JAK (1.89-fold) and STAT3 (2.95-fold), as well as the activity of VEGF promoter which was regulated by STAT3. Discussion and conclusions: ASI alleviated HF by promoting angiogenesis through JAK-STAT3 pathway, providing novel alternative strategies to prevent HF in the future.Yan-Bo SuiYu WangLi LiuFeng LiuYi-Qing ZhangTaylor & Francis Grouparticleleft coronary artery ligationcd31vegfrna interferenceTherapeutics. PharmacologyRM1-950ENPharmaceutical Biology, Vol 57, Iss 1, Pp 48-54 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	left coronary artery ligation cd31 vegf rna interference Therapeutics. Pharmacology RM1-950
spellingShingle	left coronary artery ligation cd31 vegf rna interference Therapeutics. Pharmacology RM1-950 Yan-Bo Sui Yu Wang Li Liu Feng Liu Yi-Qing Zhang Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway
description	Context: Heart failure (HF) is one of the most serious diseases worldwide. Astragaloside IV (ASI) is widely used for the treatment of cardiovascular disease in China. Objective: To evaluate the protective effect of ASI on the HF in a Sprague–Dawley rat model of left coronary artery ligation, and investigate the angiogenesis-related mechanisms. Materials and methods: Left coronary artery was ligated to induce a rat model of HF, and the rats were treated with vehicle (saline) or different doses of ASI (0.1, 0.3 and 1 mg/kg/day) by oral gavage for 6 weeks. Cardiac function was evaluated by echocardiography. Infarct size was determined by triphenyltetrazolium chloride staining. Cardiac vascular density was analyzed by microangiography. Real-time PCR, Western blot and chromatin immunoprecipitation were performed to investigate the mechanisms. Results: ASI treatment improved the body weight and survival rate of HF rats, as well as the cardiac function of HF rats, with significantly improved ejection fraction (75.27 ± 5.75% vs. 36.26 ± 4.14%) and fractional shortening (45.39 ± 3.66% vs. 17.88 ± 1.32%). ASI reduced the infarct size of the HF rats by 47%. ASI promoted angiogenesis, with increased vascular density (2.08-fold) and induced mRNA expression of CD31 (1.81-fold) and VEGF (2.70-fold) in the ischemic heart. Furthermore, ASI induced the phosphorylation of JAK (1.89-fold) and STAT3 (2.95-fold), as well as the activity of VEGF promoter which was regulated by STAT3. Discussion and conclusions: ASI alleviated HF by promoting angiogenesis through JAK-STAT3 pathway, providing novel alternative strategies to prevent HF in the future.
format	article
author	Yan-Bo Sui Yu Wang Li Liu Feng Liu Yi-Qing Zhang
author_facet	Yan-Bo Sui Yu Wang Li Liu Feng Liu Yi-Qing Zhang
author_sort	Yan-Bo Sui
title	Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway
title_short	Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway
title_full	Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway
title_fullStr	Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway
title_full_unstemmed	Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway
title_sort	astragaloside iv alleviates heart failure by promoting angiogenesis through the jak-stat3 pathway
publisher	Taylor & Francis Group
publishDate	2019
url	https://doaj.org/article/30fc41ab8e72464fab9085b4d9139a56
work_keys_str_mv	AT yanbosui astragalosideivalleviatesheartfailurebypromotingangiogenesisthroughthejakstat3pathway AT yuwang astragalosideivalleviatesheartfailurebypromotingangiogenesisthroughthejakstat3pathway AT liliu astragalosideivalleviatesheartfailurebypromotingangiogenesisthroughthejakstat3pathway AT fengliu astragalosideivalleviatesheartfailurebypromotingangiogenesisthroughthejakstat3pathway AT yiqingzhang astragalosideivalleviatesheartfailurebypromotingangiogenesisthroughthejakstat3pathway
_version_	1718425472737476608

Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway

Ejemplares similares